Atea Pharmaceuticals, Inc. AVIR · Stock Open Atea Pharmaceuticals, Inc. in new tab
Atea Pharmaceuticals, Inc. Analysis (AVIR)
Is Atea Pharmaceuticals, Inc. a good investment? Atea Pharmaceuticals, Inc. (AVIR) is currently trading at 4.61 USD. Market analysts have a consensus price target of 8.67 USD. This suggests a potential upside from current levels.
Earnings Schedule: Atea Pharmaceuticals, Inc. is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -1.39.
Investor FAQ
Does Atea Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Atea Pharmaceuticals, Inc.?
Atea Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -1.97.
Company Profile
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Community Discussion